modafinil has been researched along with Cataleptic Attacks in 39 studies
Modafinil: A benzhydryl acetamide compound, central nervous system stimulant, and CYP3A4 inducing agent that is used in the treatment of NARCOLEPSY and SLEEP WAKE DISORDERS.
modafinil : A racemate comprising equimolar amounts of armodafinil and (S)-modafinil. A central nervous system stimulant, it is used for the treatment of sleeping disorders such as narcolepsy, obstructive sleep apnoea, and shift-work sleep disorder. The optical enantiomers of modafinil have similar pharmacological actions in animals.
2-[(diphenylmethyl)sulfinyl]acetamide : A sulfoxide that is dimethylsulfoxide in which two hydrogens attached to one of the methyl groups are replaced by phenyl groups, while one hydrogen attached to the other methyl group is replaced by a carbamoyl (aminocarbonyl) group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Effects of sodium oxybate (SXB) on patients with narcolepsy with cataplexy (NC) or without cataplexy (NWOC) have not been separately evaluated in clinical trials." | 9.22 | Impact of sodium oxybate, modafinil, and combination treatment on excessive daytime sleepiness in patients who have narcolepsy with or without cataplexy. ( Black, J; Bogan, R; Carter, LP; Lai, C; Swick, T, 2016) |
| "This study was performed to evaluate the actions of baclofen and sodium oxybate, two medications with gamma-aminobutyric acid type B (GABA(B)) receptor agonist properties, on symptoms of narcolepsy in drug-naïve teenagers." | 9.14 | Narcolepsy: action of two gamma-aminobutyric acid type B agonists, baclofen and sodium oxybate. ( Guilleminault, C; Huang, YS, 2009) |
| " It is focused on the clinical and pharmacological properties of pitolisant in the treatment of narcolepsy." | 9.12 | Evaluating pitolisant as a narcolepsy treatment option. ( de Biase, S; Gigli, GL; Pellitteri, G; Valente, M, 2021) |
| "The benefit (Epworth sleepiness score, ESS; visual analog scale, patient and clinician opinions) and risks (habituation, adverse effects) of modafinil were studied in a consecutive clinical cohort of 104 IH patients (59 with long sleep time) and 126 patients with narcolepsy/cataplexy." | 7.77 | Benefit and risk of modafinil in idiopathic hypersomnia vs. narcolepsy with cataplexy. ( Arnulf, I; Dauvilliers, Y; Drouot, X; Franco, P; Golmard, JL; Lavault, S; Lecendreux, M; Leu-Semenescu, S, 2011) |
| "This is a case report of a patient with narcolepsy treated simultaneously with modafinil and tranylcypromine." | 7.72 | Concomitant use of modafinil and tranylcypromine in a patient with narcolepsy: a case report. ( Clemons, WE; Makela, E; Young, J, 2004) |
| "Effects of sodium oxybate (SXB) on patients with narcolepsy with cataplexy (NC) or without cataplexy (NWOC) have not been separately evaluated in clinical trials." | 5.22 | Impact of sodium oxybate, modafinil, and combination treatment on excessive daytime sleepiness in patients who have narcolepsy with or without cataplexy. ( Black, J; Bogan, R; Carter, LP; Lai, C; Swick, T, 2016) |
| "This study was performed to evaluate the actions of baclofen and sodium oxybate, two medications with gamma-aminobutyric acid type B (GABA(B)) receptor agonist properties, on symptoms of narcolepsy in drug-naïve teenagers." | 5.14 | Narcolepsy: action of two gamma-aminobutyric acid type B agonists, baclofen and sodium oxybate. ( Guilleminault, C; Huang, YS, 2009) |
| " It is focused on the clinical and pharmacological properties of pitolisant in the treatment of narcolepsy." | 5.12 | Evaluating pitolisant as a narcolepsy treatment option. ( de Biase, S; Gigli, GL; Pellitteri, G; Valente, M, 2021) |
| "Modafinil (200-400 mg/d), sodium oxybate 9 g/d, and pitolisant up to 40 mg/d had similar efficacy in reducing excessive day time sleepiness." | 4.98 | Multiple treatment comparison in narcolepsy: a network meta-analysis. ( Falissard, B; Lehert, P, 2018) |
| "The majority of recent papers in this field provide information about use of modafinil or sodium oxybate for treatment of sleepiness associated with narcolepsy." | 4.84 | Treatment of narcolepsy and other hypersomnias of central origin. ( Arand, DL; Auger, RR; Brooks, SN; Watson, NF; Wise, MS, 2007) |
| "Current treatment recommendations for narcolepsy suggest that modafinil should be used as a first-line treatment ahead of conventional stimulants or sodium oxybate." | 3.83 | Sleep-stage sequencing of sleep-onset REM periods in MSLT predicts treatment response in patients with narcolepsy. ( Drakatos, P; Kent, BD; Leschziner, GD; Patel, K; Thakrar, C; Williams, AJ, 2016) |
| "The benefit (Epworth sleepiness score, ESS; visual analog scale, patient and clinician opinions) and risks (habituation, adverse effects) of modafinil were studied in a consecutive clinical cohort of 104 IH patients (59 with long sleep time) and 126 patients with narcolepsy/cataplexy." | 3.77 | Benefit and risk of modafinil in idiopathic hypersomnia vs. narcolepsy with cataplexy. ( Arnulf, I; Dauvilliers, Y; Drouot, X; Franco, P; Golmard, JL; Lavault, S; Lecendreux, M; Leu-Semenescu, S, 2011) |
| "This is a case report of a patient with narcolepsy treated simultaneously with modafinil and tranylcypromine." | 3.72 | Concomitant use of modafinil and tranylcypromine in a patient with narcolepsy: a case report. ( Clemons, WE; Makela, E; Young, J, 2004) |
| "Cross-sectional survey with data obtained from the clinical trials assessing the safety and efficacy of modafinil in the treatment of narcolepsy." | 3.72 | The month-of-birth pattern in narcolepsy is moderated by cataplexy severity and may be independent of HLA-DQB1*0602. ( Harsh, JR; Mignot, EJ; Picchioni, D, 2004) |
| "Narcolepsy is an uncommon hypothalamic disorder of presumed autoimmune origin that usually requires lifelong treatment." | 2.72 | European guideline and expert statements on the management of narcolepsy in adults and children. ( Baldin, E; Bassetti, CLA; Dauvilliers, Y; Dolenc-Groselj, L; Jennum, P; Kallweit, U; Khatami, R; Lammers, GJ; Lecendreux, M; Manconi, M; Mayer, G; Partinen, M; Plazzi, G; Pollmächer, T; Reading, P; Santamaria, J; Sonka, K; Vignatelli, L, 2021) |
| "Narcolepsy is an uncommon hypothalamic disorder of presumed autoimmune origin that usually requires lifelong treatment." | 2.72 | European guideline and expert statements on the management of narcolepsy in adults and children. ( Baldin, E; Bassetti, CLA; Dauvilliers, Y; Dolenc-Groselj, L; Jennum, P; Kallweit, U; Khatami, R; Lammers, GJ; Lecendreux, M; Manconi, M; Mayer, G; Partinen, M; Plazzi, G; Pollmächer, T; Reading, P; Santamaria, J; Sonka, K; Vignatelli, L, 2021) |
| "The patients were either subjects with cataplexy who had a mean sleep latency (SL) of less than 8 minutes and two or more sleep onset rapid eye movement (REM) periods (SOREMPs) during a multiple sleep latency test, or narcoleptic patients without cataplexy but with a mean SL shorter than 5 minutes and two or more SOREMPs." | 2.68 | HLA DQB1*0602 is associated with cataplexy in 509 narcoleptic patients. ( Black, J; Grumet, FC; Guilleminault, C; Hayduk, R; Mignot, E, 1997) |
| "Narcolepsy with cataplexy is most commonly caused by an immune-mediated process including genetic and environmental factors, resulting in the selective loss of hypocretin-producing neurons." | 2.55 | Pharmacological management of narcolepsy with and without cataplexy. ( Bassetti, CL; Kallweit, U, 2017) |
| "Two subtypes of narcolepsy have been described (narcolepsy type 1 and narcolepsy type 2), both of which have similar clinical profiles, except for the presence of cataplexy, which occurs only in patients with narcolepsy type 1." | 2.55 | Narcolepsy. ( Dauvilliers, Y; Jennum, PJ; Knudsen, S; Kornum, BR; Ollila, HM; Overeem, S; Pizza, F, 2017) |
| "Narcolepsy is an emblematic, unique disease within sleep disorders that is characterised by excessive daytime sleepiness, cataplexy and other abnormal manifestations of REM sleep." | 2.48 | [Diagnostic and therapeutic update in narcolepsy]. ( Santamaria-Cano, J, 2012) |
| "Narcolepsy is a serious neurological condition in which patients are overcome by persistent, excessive feelings of fatigue and drowsiness." | 2.45 | Narcolepsy: clinical decision making for the primary care physician. ( Hazin, R; Iqbal, M; Khan, F, 2009) |
| "Cataplexy is managed by medications whereas behavioral treatment, such as avoidance of emotion, was the only treatment available in the past." | 2.44 | Therapeutic advances in narcolepsy. ( Thorpy, M, 2007) |
| "Successful treatment of hypersomnia of central origin requires an accurate diagnosis, individual tailoring of therapy to produce the fullest possible return of normal function, and regular follow-up to monitor response to treatment." | 2.44 | Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin. ( Alessi, C; Aurora, RN; Boehlecke, B; Brown, T; Chesson, AL; Friedman, L; Kapur, VK; Maganti, R; Morgenthaler, TI; Owens, J; Pancer, J; Swick, TJ; Zak, R, 2007) |
| "Narcolepsy is a disabling disease with a prevalence of 0." | 2.44 | Pediatric narcolepsy. ( Husain, AM; Peterson, PC, 2008) |
| "Modafinil has a safer side-effect profile and as a result, interest in this drug for the management of EDS in other disorders, as well as narcolepsy, has increased considerably." | 2.42 | Pharmacotherapy for excessive daytime sleepiness. ( Banerjee, D; Grunstein, RR; Vitiello, MV, 2004) |
| "Patients with narcolepsy with cataplexy reported 59 pregnancies versus 164 in the control group." | 1.48 | Narcolepsy with cataplexy and pregnancy: a case-control study. ( Calvo-Ferrandiz, E; Peraita-Adrados, R, 2018) |
| "Cataplexy is by far the most predictive feature of narcolepsy." | 1.40 | Status cataplecticus as initial presentation of late onset narcolepsy. ( Panda, S, 2014) |
| "Narcolepsy is characterised by excessive daytime sleepiness and cataplexy and has a prevalence of 25 per 100,000." | 1.36 | National narcolepsy survey. ( Crowe, C; Doherty, L; Sweeney, B, 2010) |
| "Narcolepsy is characterized by symptoms that include excessive sleepiness during the daytime, cataplexy, hypnagogic hallucinations and sleep paralysis." | 1.35 | Narcolepsy and psychotic states--a case report. ( Daliahu, Y; Melamed, Y; Paleacu, D, 2009) |
| "For treating cataplexy, the most widely used medications include the antidepressants venlafaxine, imipramine, and protriptyline, usually at lower doses than prescribed with depression, and sodium oxybate." | 1.34 | Narcolepsy: treatment issues. ( Roth, T, 2007) |
| "Modafinil, that is an effective treatment of hypersomnia, did not alleviate the symptoms of fibrositis in the short term." | 1.29 | Fibrositis syndrome and narcolepsy. ( Bernard, PM; Disdier, P; Genton, P; Milandre, C; Millet, Y, 1993) |
| "In contrast, the results of cataplexy testing demonstrate that amphetamine (2." | 1.29 | Comparative effects of modafinil and amphetamine on daytime sleepiness and cataplexy of narcoleptic dogs. ( Dement, WC; Mignot, E; Nishino, S; Shelton, J; Vaught, J, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (10.26) | 18.2507 |
| 2000's | 15 (38.46) | 29.6817 |
| 2010's | 16 (41.03) | 24.3611 |
| 2020's | 4 (10.26) | 2.80 |
| Authors | Studies |
|---|---|
| Thorpy, MJ | 2 |
| Bogan, RK | 1 |
| de Biase, S | 1 |
| Pellitteri, G | 1 |
| Gigli, GL | 1 |
| Valente, M | 1 |
| Bassetti, CLA | 2 |
| Kallweit, U | 3 |
| Vignatelli, L | 2 |
| Plazzi, G | 4 |
| Lecendreux, M | 4 |
| Baldin, E | 2 |
| Dolenc-Groselj, L | 2 |
| Jennum, P | 2 |
| Khatami, R | 2 |
| Manconi, M | 2 |
| Mayer, G | 5 |
| Partinen, M | 2 |
| Pollmächer, T | 2 |
| Reading, P | 2 |
| Santamaria, J | 2 |
| Sonka, K | 2 |
| Dauvilliers, Y | 7 |
| Lammers, GJ | 3 |
| Bassetti, CL | 2 |
| Calvo-Ferrandiz, E | 1 |
| Peraita-Adrados, R | 1 |
| Dinkelacker, V | 1 |
| Nguyen-Michel, VH | 1 |
| Thivard, L | 1 |
| Navarro, V | 1 |
| Adam, C | 1 |
| Pallanca, O | 1 |
| Arnulf, I | 4 |
| Antelmi, E | 1 |
| Pizza, F | 2 |
| Vandi, S | 1 |
| Lehert, P | 2 |
| Falissard, B | 1 |
| Szabo, ST | 1 |
| Peever, JH | 1 |
| Kilduff, TS | 1 |
| Panda, S | 1 |
| van der Heide, A | 1 |
| van Schie, MK | 1 |
| Ding, CL | 1 |
| van Dijk, JG | 1 |
| Lavault, S | 2 |
| Lopez, R | 1 |
| Inocente, CO | 1 |
| Konofal, E | 1 |
| Cortese, S | 1 |
| Franco, P | 2 |
| Drakatos, P | 1 |
| Patel, K | 1 |
| Thakrar, C | 1 |
| Williams, AJ | 1 |
| Kent, BD | 1 |
| Leschziner, GD | 1 |
| Black, J | 2 |
| Swick, T | 1 |
| Bogan, R | 1 |
| Lai, C | 1 |
| Carter, LP | 1 |
| Kornum, BR | 1 |
| Knudsen, S | 1 |
| Ollila, HM | 1 |
| Jennum, PJ | 1 |
| Overeem, S | 1 |
| Hoque, R | 1 |
| Chesson, AL | 2 |
| Paquereau, J | 1 |
| Bastuji, H | 1 |
| Drouot, X | 2 |
| Weil, JS | 1 |
| Viot-Blanc, V | 1 |
| Huang, YS | 1 |
| Guilleminault, C | 2 |
| Melamed, Y | 1 |
| Daliahu, Y | 1 |
| Paleacu, D | 1 |
| Khan, F | 1 |
| Hazin, R | 1 |
| Iqbal, M | 1 |
| Doherty, L | 1 |
| Crowe, C | 1 |
| Sweeney, B | 1 |
| Soltanifar, S | 1 |
| Russell, R | 1 |
| Leu-Semenescu, S | 1 |
| Golmard, JL | 1 |
| Santamaria-Cano, J | 1 |
| Mignot, E | 4 |
| Banerjee, D | 1 |
| Vitiello, MV | 1 |
| Grunstein, RR | 1 |
| Clemons, WE | 1 |
| Makela, E | 1 |
| Young, J | 1 |
| Picchioni, D | 1 |
| Mignot, EJ | 1 |
| Harsh, JR | 1 |
| Parmeggiani, A | 1 |
| Lin, L | 1 |
| Scano, MC | 1 |
| Posar, A | 1 |
| Bernardi, F | 1 |
| Lodi, R | 1 |
| Tonon, C | 1 |
| Barbiroli, B | 1 |
| Montagna, P | 1 |
| Cicognani, A | 1 |
| Thorpy, M | 1 |
| Roth, T | 1 |
| Morgenthaler, TI | 1 |
| Kapur, VK | 1 |
| Brown, T | 1 |
| Swick, TJ | 1 |
| Alessi, C | 1 |
| Aurora, RN | 1 |
| Boehlecke, B | 1 |
| Friedman, L | 1 |
| Maganti, R | 1 |
| Owens, J | 1 |
| Pancer, J | 1 |
| Zak, R | 1 |
| Wise, MS | 1 |
| Arand, DL | 1 |
| Auger, RR | 1 |
| Brooks, SN | 1 |
| Watson, NF | 1 |
| Peterson, PC | 1 |
| Husain, AM | 1 |
| Laffont, F | 1 |
| Minz, M | 1 |
| Disdier, P | 1 |
| Genton, P | 1 |
| Milandre, C | 1 |
| Bernard, PM | 1 |
| Millet, Y | 1 |
| Shelton, J | 1 |
| Nishino, S | 1 |
| Vaught, J | 1 |
| Dement, WC | 1 |
| Hayduk, R | 1 |
| Grumet, FC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Treating Comorbid Depression of Patients With Narcolepsy by Intermittent Theta Burst Stimulation: A Preliminary Study[NCT05884112] | 105 participants (Anticipated) | Interventional | 2023-02-22 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
16 reviews available for modafinil and Cataleptic Attacks
| Article | Year |
|---|---|
Update on the pharmacologic management of narcolepsy: mechanisms of action and clinical implications.
Topics: Adult; Cataplexy; Humans; Methylphenidate; Modafinil; Narcolepsy; Sodium Oxybate | 2020 |
Evaluating pitolisant as a narcolepsy treatment option.
Topics: Animals; Cataplexy; Humans; Modafinil; Narcolepsy; Piperidines; Sleep; Sodium Oxybate; Treatment Out | 2021 |
European guideline and expert statements on the management of narcolepsy in adults and children.
Topics: Adult; Cataplexy; Child; Humans; Modafinil; Narcolepsy; Sleep; Sodium Oxybate | 2021 |
European guideline and expert statements on the management of narcolepsy in adults and children.
Topics: Adult; Cataplexy; Child; Humans; Modafinil; Narcolepsy; Sleep; Sodium Oxybate | 2021 |
Pharmacological management of narcolepsy with and without cataplexy.
Topics: Adult; Benzhydryl Compounds; Cataplexy; Drug Therapy, Combination; Humans; Modafinil; Narcolepsy; Ne | 2017 |
Multiple treatment comparison in narcolepsy: a network meta-analysis.
Topics: Adult; Cataplexy; Humans; Modafinil; Narcolepsy; Network Meta-Analysis; Odds Ratio; Piperidines; Ris | 2018 |
Neurobiological and immunogenetic aspects of narcolepsy: Implications for pharmacotherapy.
Topics: Adjuvants, Anesthesia; Antidepressive Agents; Antidepressive Agents, Tricyclic; Cataplexy; Central N | 2019 |
Narcolepsy.
Topics: Adjuvants, Anesthesia; Benzhydryl Compounds; Biomarkers; Cataplexy; Genetic Predisposition to Diseas | 2017 |
Narcolepsy: clinical decision making for the primary care physician.
Topics: Benzhydryl Compounds; Biomarkers; Cataplexy; Central Nervous System Stimulants; Decision Making; Dia | 2009 |
[Diagnostic and therapeutic update in narcolepsy].
Topics: Adolescent; Adult; Age of Onset; Animals; Autoimmune Diseases; Benzhydryl Compounds; Cataplexy; Chil | 2012 |
An update on the pharmacotherapy of excessive daytime sleepiness and cataplexy.
Topics: Animals; Antidepressive Agents; Benzhydryl Compounds; Cataplexy; Central Nervous System Stimulants; | 2004 |
Pharmacotherapy for excessive daytime sleepiness.
Topics: Amphetamines; Benzhydryl Compounds; Biological Availability; Cataplexy; Central Nervous System Stimu | 2004 |
Therapeutic advances in narcolepsy.
Topics: Benzhydryl Compounds; Cataplexy; Central Nervous System Stimulants; Humans; Immunotherapy; Methylphe | 2007 |
Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin.
Topics: Antidepressive Agents, Tricyclic; Benzhydryl Compounds; Cataplexy; Central Nervous System Stimulants | 2007 |
Treatment of narcolepsy and other hypersomnias of central origin.
Topics: Antidepressive Agents, Tricyclic; Benzhydryl Compounds; Cataplexy; Central Nervous System Stimulants | 2007 |
Pediatric narcolepsy.
Topics: Benzhydryl Compounds; Cataplexy; Central Nervous System Stimulants; Child; Dextroamphetamine; Ghreli | 2008 |
4 trials available for modafinil and Cataleptic Attacks
| Article | Year |
|---|---|
Comparing Treatment Effect Measurements in Narcolepsy: The Sustained Attention to Response Task, Epworth Sleepiness Scale and Maintenance of Wakefulness Test.
Topics: Adult; Attention; Benzhydryl Compounds; Cataplexy; Double-Blind Method; Female; Humans; Male; Modafi | 2015 |
Impact of sodium oxybate, modafinil, and combination treatment on excessive daytime sleepiness in patients who have narcolepsy with or without cataplexy.
Topics: Adjuvants, Anesthesia; Adult; Benzhydryl Compounds; Cataplexy; Drug Therapy, Combination; Female; Hu | 2016 |
Narcolepsy: action of two gamma-aminobutyric acid type B agonists, baclofen and sodium oxybate.
Topics: Adolescent; Baclofen; Benzhydryl Compounds; Cataplexy; Central Nervous System Stimulants; Female; Fo | 2009 |
HLA DQB1*0602 is associated with cataplexy in 509 narcoleptic patients.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Cataplexy; Central Nervous System Stimulants; Female; | 1997 |
19 other studies available for modafinil and Cataleptic Attacks
| Article | Year |
|---|---|
Narcolepsy with cataplexy and pregnancy: a case-control study.
Topics: Adult; Breast Feeding; Case-Control Studies; Cataplexy; Central Nervous System Stimulants; Cesarean | 2018 |
"I feel my arm shaking": partial cataplexy mistaken for drug-resistant focal epilepsy.
Topics: Arm; Cataplexy; Diagnostic Errors; Drug Resistant Epilepsy; Electroencephalography; Humans; Male; Mo | 2017 |
Stereotyped episodes of aphasia and immobility: how cataplexy mimics stroke in an elderly patient.
Topics: Adjuvants, Anesthesia; Age of Onset; Aphasia; Cataplexy; Diagnostic Errors; Electroencephalography; | 2017 |
Status cataplecticus as initial presentation of late onset narcolepsy.
Topics: Benzhydryl Compounds; Cataplexy; Clomipramine; Diagnosis, Differential; Electroencephalography; Foll | 2014 |
Attention-Deficit/Hyperactivity Disorder (ADHD) Symptoms in Pediatric Narcolepsy: A Cross-Sectional Study.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Benzhydryl Compounds; Case-Control Studie | 2015 |
Sleep-stage sequencing of sleep-onset REM periods in MSLT predicts treatment response in patients with narcolepsy.
Topics: Adult; Benzhydryl Compounds; Cataplexy; Central Nervous System Stimulants; Female; Humans; Male; Mod | 2016 |
Conception, pregnancy, delivery, and breastfeeding in a narcoleptic patient with cataplexy.
Topics: Adult; Benzhydryl Compounds; Breast Feeding; Cataplexy; Central Nervous System Stimulants; Contraind | 2008 |
Psychological health in central hypersomnias: the French Harmony study.
Topics: Adult; Antidepressive Agents; Benzhydryl Compounds; Cataplexy; Central Nervous System Stimulants; Co | 2009 |
Narcolepsy and psychotic states--a case report.
Topics: Antipsychotic Agents; Benzhydryl Compounds; Cataplexy; Central Nervous System Stimulants; Comorbidit | 2009 |
National narcolepsy survey.
Topics: Benzhydryl Compounds; Cataplexy; Central Nervous System Stimulants; Health Surveys; Humans; Intracel | 2010 |
Neuraxial anaesthesia for caesarean section in a patient with narcolepsy and cataplexy.
Topics: Adult; Anesthesia, Epidural; Anesthesia, Obstetrical; Antidepressive Agents, Second-Generation; Benz | 2010 |
Benefit and risk of modafinil in idiopathic hypersomnia vs. narcolepsy with cataplexy.
Topics: Adult; Benzhydryl Compounds; Cataplexy; Central Nervous System Stimulants; Cohort Studies; Databases | 2011 |
Concomitant use of modafinil and tranylcypromine in a patient with narcolepsy: a case report.
Topics: Benzhydryl Compounds; Blood Pressure; Cataplexy; Central Nervous System Stimulants; Comorbidity; Dep | 2004 |
The month-of-birth pattern in narcolepsy is moderated by cataplexy severity and may be independent of HLA-DQB1*0602.
Topics: Adult; Age of Onset; Aged; Benzhydryl Compounds; Brain; Cataplexy; Central Nervous System Stimulants | 2004 |
Narcolepsy-cataplexy associated with precocious puberty.
Topics: Aspartic Acid; Benzhydryl Compounds; Cataplexy; Child; Creatine; Cyclohexanols; Disorders of Excessi | 2006 |
Narcolepsy: treatment issues.
Topics: Antidepressive Agents; Benzhydryl Compounds; Cataplexy; Central Nervous System Stimulants; Circadian | 2007 |
Modafinil in diurnal sleepiness. A study of 123 patients.
Topics: Adolescent; Adult; Age of Onset; Aged; Benzhydryl Compounds; Cataplexy; Central Nervous System Stimu | 1994 |
Fibrositis syndrome and narcolepsy.
Topics: Aged; Benzhydryl Compounds; Cataplexy; Central Nervous System Stimulants; Female; Fibromyalgia; Huma | 1993 |
Comparative effects of modafinil and amphetamine on daytime sleepiness and cataplexy of narcoleptic dogs.
Topics: Amphetamine; Animals; Behavior, Animal; Benzhydryl Compounds; Cataplexy; Central Nervous System Stim | 1995 |